Duration of androgen suppression in the treatment of prostate cancer.

BACKGROUND The combination of radiotherapy plus long-term medical suppression of androgens (> or = 2 years) improves overall survival in patients with locally advanced prostate cancer. We compared the use of radiotherapy plus short-term androgen suppression with the use of radiotherapy plus long-term androgen suppression in the treatment of locally advanced prostate cancer. METHODS We randomly assigned patients with locally advanced prostate cancer who had received external-beam radiotherapy plus 6 months of androgen suppression to two groups, one to receive no further treatment (short-term suppression) and the other to receive 2.5 years of further treatment with a luteinizing hormone-releasing hormone agonist (long-term suppression). An outcome of noninferiority of short-term androgen suppression as compared with long-term suppression required a hazard ratio of more than 1.35 for overall survival, with a one-sided alpha level of 0.05. An interim analysis showed futility, and the results are presented with an adjusted one-sided alpha level of 0.0429. RESULTS A total of 1113 men were registered, of whom 970 were randomly assigned, 483 to short-term suppression and 487 to long-term suppression. After a median follow-up of 6.4 years, 132 patients in the short-term group and 98 in the long-term group had died; the number of deaths due to prostate cancer was 47 in the short-term group and 29 in the long-term group. The 5-year overall mortality for short-term and long-term suppression was 19.0% and 15.2%, respectively; the observed hazard ratio was 1.42 (upper 95.71% confidence limit, 1.79; P=0.65 for noninferiority). Adverse events in both groups included fatigue, diminished sexual function, and hot flushes. CONCLUSIONS The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapy plus 3 years of androgen suppression in the treatment of locally advanced prostate cancer. (ClinicalTrials.gov number, NCT00003026.)

[1]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[2]  M. Piérart,et al.  Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study , 2008 .

[3]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[6]  N. Keating,et al.  Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Dobs,et al.  Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. D'Amico.  Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Grignon,et al.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. , 2005, International journal of radiation oncology, biology, physics.

[10]  J. Goodwin,et al.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The New England journal of medicine.

[11]  M. Bolla,et al.  Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Jacques Bernier,et al.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial , 2002, The Lancet.

[13]  J. Stanford,et al.  Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Lubeck,et al.  The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. , 2001, Urology.

[15]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[16]  A. Hanlon,et al.  External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990 , 1995 .

[17]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[18]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[19]  C. Patte,et al.  How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma. , 1993, Statistics in medicine.

[20]  J. S. D. Cani,et al.  Group sequential designs using a family of type I error probability spending functions. , 1990, Statistics in medicine.

[21]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[22]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[23]  E. Crawford,et al.  Adverse events associated with hormonal therapy for prostate cancer. , 2005, Reviews in urology.

[24]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[26]  L. Freedman.  Tables of the number of patients required in clinical trials using the logrank test. , 1982, Statistics in medicine.